Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease

The ALZpath difference

ALZpath provides diagnostic tools and expertise in Alzheimer’s disease.  We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.

Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification

A timely and accessible diagnosis

Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:

  • Simple
  • Accessible
  • Timely
  • Cost-effective
  • Less invasive

pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.

ALZpath News

Invaluable study provides compelling evidence for the clinical use of ALZpath assay

September 26, 2023

Dr. Therriault and their dedicated team have launched a preprint in The Lancet reporting on their essential study delving into the performance of pTau217 assays. The findings from this research strongly support the diagnostic excellence of the ALZpath pTau217 assay for identifying Alzheimer’s disease, and its robust association with amyloid-PET and tau-PET – the current clinical standards for Alzheimer’s pathology diagnosis.

Pivotal study reports biological and analytical variation for pTau217

AUGUST 13, 2023

Dr. Wagner Brum and their exceptional team have illuminated the biological variation in leading blood-based biomarkers for Alzheimer’s disease, and found pTau217 has low individual biological variation compared to pTau181. We are honored that this study utilized our ALZpath pTau217 assay to determine the biological variation in pTau217.

ALZpath Announces Partnership with ADDF for clinical Alzheimer's diagnostic launch

JULY 18, 2023

ALZpath is proud to share that we have received funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate clinical availability of our blood based Alzheimer’s diagnostic test. This investment comes at a pivotal time as the first approval of a disease modifying therapy ushering in a new era in Alzheimer’s clinical care.

Breakthrough study reveals diagnostic power of ALZpath pTau217 assay

JULY 12, 2023

The ALZpath pTau217 assay has been featured in a crucial evaluation of biomarkers of Alzheimer’s disease pathology. Dr. Nicholas Ashton and team demonstrated our ALZpath pTau217 assay can accurately identify and longitudinally monitor Alzheimer’s disease pathology, including in preclinical stages.